PL374364A1 - Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania - Google Patents
Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowaniaInfo
- Publication number
- PL374364A1 PL374364A1 PL03374364A PL37436403A PL374364A1 PL 374364 A1 PL374364 A1 PL 374364A1 PL 03374364 A PL03374364 A PL 03374364A PL 37436403 A PL37436403 A PL 37436403A PL 374364 A1 PL374364 A1 PL 374364A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibitors
- well
- coa reductase
- antihypertensive agents
- hmg coa
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 229940030600 antihypertensive agent Drugs 0.000 title 1
- 239000002220 antihypertensive agent Substances 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39371502P | 2002-07-02 | 2002-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL374364A1 true PL374364A1 (pl) | 2005-10-17 |
Family
ID=30115632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03374364A PL374364A1 (pl) | 2002-07-02 | 2003-06-20 | Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7071210B2 (pl) |
| EP (1) | EP1519752A1 (pl) |
| JP (1) | JP2005538977A (pl) |
| CN (1) | CN1665536A (pl) |
| AU (1) | AU2003238622A1 (pl) |
| BR (1) | BR0312334A (pl) |
| CA (1) | CA2490988A1 (pl) |
| MX (1) | MXPA05000261A (pl) |
| PL (1) | PL374364A1 (pl) |
| TW (1) | TW200406221A (pl) |
| WO (1) | WO2004004777A1 (pl) |
| ZA (1) | ZA200410212B (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| RS20050532A (sr) | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| BRPI0408442A (pt) * | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
| KR20080008440A (ko) * | 2003-03-17 | 2008-01-23 | 니뽄 다바코 산교 가부시키가이샤 | Ｃｅｔｐ 억제제의 약제학적 조성물 |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| WO2005033082A2 (en) * | 2003-09-30 | 2005-04-14 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| WO2005117869A1 (en) * | 2004-05-12 | 2005-12-15 | Sepracor Inc. | Combinations comprising (s)-amlodipine and a cholesteryl ester transfer protein inhibitor, and methods for reducing hypertension |
| CA2570496A1 (en) * | 2004-06-24 | 2006-01-05 | Galapagos N.V. | Methods and compositions to promote bone homeostasis |
| US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| MX2007007919A (es) * | 2004-12-31 | 2008-01-22 | Reddy Us Therapeutics Inc | Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp). |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| KR101436644B1 (ko) * | 2006-01-31 | 2014-09-01 | 코와 가부시키가이샤 | 당뇨병 치료제 |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| CA2651942A1 (en) * | 2006-05-11 | 2008-07-03 | Janssen Pharmaceutica N.V. | 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors |
| TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| IN2014CN02290A (pl) | 2011-09-27 | 2015-06-19 | Reddys Lab Ltd Dr | |
| KR101436547B1 (ko) * | 2011-11-30 | 2014-09-02 | 주식회사 대웅제약 | 고지혈증의 예방 또는 치료용 약학 조성물 |
| WO2014004987A2 (en) * | 2012-06-30 | 2014-01-03 | Hellstrom Harold R | Short-term infarction-based test for investigative drugs |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714274D0 (en) * | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| YU2700A (sh) * | 1997-08-29 | 2002-06-19 | Pfizer Products Inc. | Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| PL353483A1 (pl) * | 1999-05-27 | 2003-11-17 | Pfizer Products Inc. | Wspólne proleki amlodypiny i atorwastatyny |
| HN2000000050A (es) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
| EP1125579A3 (en) * | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
| CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| US20030092745A1 (en) * | 2000-02-25 | 2003-05-15 | Pfizer Inc. | Combination therapy |
| US6812345B2 (en) * | 2000-06-15 | 2004-11-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| JP2004506008A (ja) | 2000-08-15 | 2004-02-26 | ファイザー・プロダクツ・インク | 治療コンビネーション |
| JP4284017B2 (ja) * | 2000-10-06 | 2009-06-24 | 武田薬品工業株式会社 | 固形製剤 |
| US7510728B2 (en) * | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
| US6737430B2 (en) * | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| CA2430760A1 (en) * | 2000-12-13 | 2002-06-20 | Shionogi & Co., Ltd. | Antilipemic agents |
| JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
| WO2002087556A2 (en) | 2001-04-11 | 2002-11-07 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| US20040053842A1 (en) | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US6956627B2 (en) * | 2002-09-10 | 2005-10-18 | Au Optronics Corp. | Electronic apparatus with liquid crystal display, digitizer, and housing, fastened by screws |
-
2003
- 2003-06-10 US US10/459,026 patent/US7071210B2/en not_active Expired - Fee Related
- 2003-06-20 BR BR0312334-0A patent/BR0312334A/pt not_active IP Right Cessation
- 2003-06-20 CN CN038155583A patent/CN1665536A/zh active Pending
- 2003-06-20 MX MXPA05000261A patent/MXPA05000261A/es unknown
- 2003-06-20 JP JP2004519070A patent/JP2005538977A/ja active Pending
- 2003-06-20 AU AU2003238622A patent/AU2003238622A1/en not_active Abandoned
- 2003-06-20 CA CA002490988A patent/CA2490988A1/en not_active Abandoned
- 2003-06-20 PL PL03374364A patent/PL374364A1/pl not_active Application Discontinuation
- 2003-06-20 EP EP03732962A patent/EP1519752A1/en not_active Ceased
- 2003-06-20 WO PCT/IB2003/002697 patent/WO2004004777A1/en not_active Ceased
- 2003-06-27 TW TW092117695A patent/TW200406221A/zh unknown
-
2004
- 2004-12-17 ZA ZA200410212A patent/ZA200410212B/en unknown
-
2006
- 2006-02-01 US US11/345,796 patent/US20060128751A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060128751A1 (en) | 2006-06-15 |
| BR0312334A (pt) | 2005-04-12 |
| CN1665536A (zh) | 2005-09-07 |
| TW200406221A (en) | 2004-05-01 |
| ZA200410212B (en) | 2006-04-26 |
| US20040039018A1 (en) | 2004-02-26 |
| EP1519752A1 (en) | 2005-04-06 |
| AU2003238622A1 (en) | 2004-01-23 |
| JP2005538977A (ja) | 2005-12-22 |
| WO2004004777A1 (en) | 2004-01-15 |
| US7071210B2 (en) | 2006-07-04 |
| CA2490988A1 (en) | 2004-01-15 |
| MXPA05000261A (es) | 2005-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165328A0 (en) | Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents | |
| AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
| AU2003303128A8 (en) | Inhibitors and methods of use thereof | |
| IL161258A0 (en) | Heterocyclic compounds and methods of use | |
| PL376575A1 (pl) | Podstawione związki heterocykliczne oraz sposoby wykorzystania | |
| IL159588A0 (en) | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor | |
| IL163929A0 (en) | Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulinsensitizer | |
| EP1549614A4 (en) | VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION | |
| AU2003213673A1 (en) | Pin1-modulating compounds and methods of use thereof | |
| AU2003259735A8 (en) | Small-mer compositions and methods of use | |
| IL173936A0 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| PL375586A1 (pl) | Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystania | |
| EP1549316A4 (en) | HAMMER OF TFGbeta | |
| AU2003281324A8 (en) | Antisense modulation of hmg-coa reductase expression | |
| IL157659A0 (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| AU2003261449A1 (en) | Compositions for rna interference and methods of use thereof | |
| PL359820A1 (pl) | Inhibitory reduktazy HMG-CoA i sposób leczenia | |
| EP1684754A4 (en) | HMG COA REDUCTASE INHIBITORS AND METHOD | |
| AU2003278832A8 (en) | Optical biosensors and methods of use thereof | |
| ZA200501381B (en) | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | |
| AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
| PL371217A1 (pl) | Inhibitory integryny alfaVbeta6 | |
| PL374581A1 (pl) | Diaminotiazole przydatne jako selektywne inhibitory CDK4 | |
| AU2002306624A1 (en) | Heterocyclic analgesic compounds and methods of use thereof | |
| AU2003275056A8 (en) | Novel lapacho compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |